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Abstract
Background: The beneficial effects of early statin use in kidney transplant recipients, especially those on
tacrolimus-based immunosuppression, are not well established. We evaluated the predictors of statin use following
kidney transplantation and examined its association with patient and allograft survival.
Methods: We examined 615 consecutive patients who underwent kidney transplant at our institution between
January 1998 and January 2002. Statin use was assessed at baseline and 3, 6, 9, and 12 months following kidney
transplant. Patients were followed for allograft and patient survival.
Results: 36% of the 615 kidney transplant recipients were treated with statin treatment. Statin use increased over
the course of the study period. Older age, elevated body mass index, higher triglyceride levels,
hypercholesterolemia, diabetes, history of myocardial infarction were associated with higher rates of statin use;
elevated alkaline phosphatase levels and CMV IgG seropositivity were associated with less statin use. Older age,
elevated BMI and hypercholesterolemia remained significant predictors of increased statin use after accounting for
covariates using multiple regression. The early use of statins was not associated with improvements in unadjusted
patient survival [HR 0.99; 95%CI 0.72-1.37] or graft survival [HR 0.97; 95% CI 0.76-1.24]. The risks of death and graft
survival were not consistently reduced with exposure to statin using either adjusted models or propensity scores in
Cox Proportional Hazards models.
Conclusions: In a kidney transplant population primarily receiving tacrolimus-based immunosuppression, early
statin use was not associated with significantly improved graft or patient survival.
Background
Statins have known effects in reducing cardiac as well as
overall mortality in the general population [1]. The ben-
efits of statins in reducing overall mortality are not well
established in patients with kidney disease, including the
kidney transplant population. A randomized controlled
trial in diabetic hemodialysis patients showed no
improvement in survival in those patients randomized
to receive atorvastatin compared to placebo [2]. The
Assessment of LEscol Renal Transplantation (ALERT)
study is the only randomized controlled trial of statins
in kidney transplant patients [3]. This trial found no sta-
tistically significant benefit of fluvastatin compared to
placebo in achieving the primary outcome of a reduction
in major adverse cardiac events (MACE); in addition, no
statistical difference was seen in the overall mortality or
graft survival between the fluvastatin and placebo
groups. However, a 2 year extension of the ALERT trial
showed that patients randomized to the fluvastatin
group had a reduced risk of MACE; there remained no
significant difference in overall mortality and graft loss
between the groups [4]. The findings of the ALERT trial
suggest that the timing of statin use may determine the
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was a greater reduction in major cardiac events in those
patients initiating statin therapy early (years 0-2) than in
those initiating statin therapy late (>6 years) following
transplantation [5]. A recently published observational
study used the Austrian transplantation registry to ana-
lyze the efficacy of statins in kidney transplant patients
[6]. This study showed improved patient survival but no
improvement in graft survival in patients receiving
statins.
While the cholesterol lowering effect of 3-Hydroxy-3-
methyl glutaryl coenzyme A (HMG CoA) reductase
inhibitors (statins) is well-established, recent reports
suggest that there are an increasing number of extra-
lipid effects, including various anti-inflammatory and
immunomodulatory actions [7-9]. Possible mechanisms
that have been proposed by which statins may specifi-
cally benefit the transplant population include the
alteration of free drug levels, the modulation of throm-
botic processes and endothelial function, and the effect
on inflammatory and immune responses–both depen-
dent and independent of inhibition of the HMG-CoA
reductase enzyme [7,8,10,11]. Observational and experi-
mental evidence in lung, [12] pancreas, [13] and heart
[14-16] transplantation suggests that treatment with sta-
tins leads to an increased survival and fewer episodes of
transplant rejection, although the mechanism by which
this occurs has not been fully delineated. Despite these
positive findings in extra-renal solid organ transplants,
an immunologic benefit has not been clearly demon-
strated following renal transplantation [3-5,17-25]. Early
pilot and single-center retrospective studies found a
positive effect of various statins on the incidence of
acute rejection and patient survival in kidney transplan-
tation [18,24].
There are many potential factors that may affect statin
use in the clinical setting. We are not aware of any stu-
dies in the published literature examining predictors of
statin use in kidney transplantation. Furthermore, in
contrast to cyclosporine, tacrolimus is less likely to
induce dyslipidemia, and thus lead to the initiation of
statin therapy for lipid management [26]. Hence, the
determinants of statin use in the kidney transplant
population, and the extent to which there is a benefit of
early statin use following kidney transplantation in the
contemporary kidney transplantation population, parti-
cularly in those receiving tacrolimus based immunosup-
pression, remains unclear following the ALERT Study.
In order to address these gaps in knowledge regarding
the determinants and outcomes of statin use in kidney
transplantation, this report expands the existing evi-
dence by examining the effect of statins in an incident
cohort of kidney transplant recipients managed predo-
minantly with tacrolimus-based immunosuppression and
assesses the extent to which early statin use is associated
with benefit. First, this report evaluates factors asso-
ciated with statin use in a community-based setting with
contemporary immunosuppression. Second, we examine
the potential benefits of using statins following kidney
transplantation in this cohort of kidney transplant
patients followed prospectively for medication use, and
graft and patient survival.
Methods
Patient Population
In this historical cohort study, we examined all 715 con-
secutive patients who received a renal transplant from
either deceased or living donors at our institution
between January 1998 and January 2002 and include fol-
low-up until July 2005. 615 patients who survived and
had a functioning graft a year after transplantation were
included in the analysis to avoid immortality time bias.
Greater than ninety percent of patients received a tacro-
limus based immunosuppressive regimen. An induction,
initially with thymoglobulin, and later with alemtuzu-
mab, and tacrolimus monotherapy protocol was intro-
duced in July 2001, and 15% of the patients included in
this study were treated with this regimen, as previously
described [27,28]. Under this new protocol, additional
agents, such as antimetabolites, are reserved for the
management of patients experiencing episodes of rejec-
tion or deemed to be at high risk of rejection, at the dis-
cretion of the treating transplant physician. Sirolimus
was used in 8.5% and azathioprine in 1% of our patients.
Sixty-eight percent of patients received maintenance
steroid therapy. The use of maintenance steroids
decreased over the study period. Only 2 out of the 615
patients received cyclosporine based immunosuppres-
sion. Immunosuppresive medications were routinely
evaluated by frequent blood level determinations and
adjusted for clinical events without consideration of sta-
tin use.
Human Subjects Protection
Information used for our analyses was obtained through
an honest broker system from prospectively recorded
databases maintained by the University of Pittsburgh
Medical Center and Starzl Transplantation Institute,
under the auspices of, and with formal approval by, the
Institutional Review Board of the University of Pitts-
burgh (Pittsburgh, PA). Research data were coded to
prevent the identification of subjects.
Clinical Treatment
Choice and dosing of statins were prescribed at the dis-
cretion of both the physicians in our transplant clinic as
well as the patients’ non-transplant physicians. Lipid
measures were obtained pre-operatively on the day of
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part of routine clinic blood work. At the time of this
study, routine clinic blood work included only total cho-
lesterol and triglyceride levels. Full lipid profiles were
not available for the majority of our patients. Statin use
was assessed in clinic as part of the routine detailed
review with patients of their medications, conducted by
a post-operative transplant coordinator at baseline and
3, 6, 9, and 12 months following transplantation. We
classified patients with a significant exposure to statin
therapy from those who discontinued the drug after
only a brief exposure. There were 19 patients who
received statins during only a single time point. For the
purpose of this study, these patients were included with
the control group. All patients recorded as receiving any
statin at 2 or more time points, up to one year following
transplantation, were assigned to the treatment group.
Detailed information regarding pre-transplant statin use
was not available.
Data Collection
The primary outcome measures were graft failure and
patient death. Graft failure was defined as loss of renal
function requiring re-transplantation or initiation of long-
term dialysis. Data were recorded into the transplant
patient database by patient care coordinators. For patients
whose grafts failed and who returned to dialysis, the coor-
dinators relied on various sources including reports from
outside nephrologists, dialysis units, patient families, and
newspaper obituaries to update the vital status.
Baseline patient comorbidity was assessed using speci-
fic individual comorbid conditions as well as by using
an adjusted Charlson comorbidity index to determine
the effects of composite comorbidity on the specified
outcomes, as previously described [29]. Additional cov-
ariates included patient demographics (age, gender,
race), clinical factors (cause of ESRD, previous trans-
plant, body mass index [BMI], BMI
2, immunosuppres-
sive protocol), and laboratory values (liver function tests,
CMV and hepatitis B and C status, total cholesterol),
year of transplantation, as well as donor factors (living
or deceased, age, antigen matching) and transplant pro-
cedure characteristics (cold ischemia time and delayed
graft function, defined as the need for dialysis in the
first week following transplantation).
Statistical analysis
Baseline demographic, laboratory, and transplant factors
are described as means and standard deviations for con-
tinuous variables and as frequency distributions for
dichotomous variables. Statistical significance of the dif-
ferences between groups was tested using two-sample
t-tests or ANOVA for continuous variables and Chi-
square tests for categorical variables.
Determinants of statin use
We created a multiple logistic regression model to iden-
tify factors independently associated with the use of sta-
tins following kidney transplantation. All covariates with
p < 0.2 in the univariate analysis were entered initially,
and the parameter estimates of predictors of statin
exposure were examined after the removal of each
potential covariate with p > 0.20 to assess for possible
confounding. In the final model, race and gender were
forced into the model, which included age, body mass
index, liver disease, CMV IgG seropositivity, diabetes,
MI, cholesterol, triglycerides, and history of previous
transplant. In our analysis of predictors of statin use, a
number of study patients lacked data for one or more
variables. In order to assess the influence of missing
data, we examined the multiple logistic regression para-
meter estimates using a complete case analysis, interpo-
lating missing values, and substituting average values.
Statin use increased over the study period; in order to
adjust for this, we included both the year of transplant
and a sequential transplant identification key into the
regression model to assess whether it affected our
analysis
Survival analysis
We hypothesized that the use of statins would be asso-
ciated with longer patient and graft survival. While
statin use was assessed over the first year after trans-
plantation, all analyses of graft and patient survival were
conducted from one year after transplantation in order
to avoid an immortality time bias [30]. Similarly, to
decrease the effect of confounding by factors such as
significant post-operative morbidity or serious co-mor-
bid illness on the use of statins, we limited our survival
analyses to patients who survived, and to grafts that
functioned, at least one year. Patients lost to follow up
and those remaining enrolled at the close of the study
were censored at the time of those events. Univariate
and multivariate Cox proportional hazards models were
used for time-to-event analyses to assess the crude and
independent associations between statin use and study
outcomes. In order to adjust for baseline factors with
potential to confound the relationship of statin use to
subsequent outcomes, baseline covariates significantly
associated with statin use and other major demographic
covariates thought to be associated with survival were
entered into the Cox proportional hazards regression
model. We examined survival models using additional
groups of variables to identify potential confounding. To
account for the effect of baseline creatinine on graft sur-
vival, we adjusted for creatinine at 12 months when
examining the association between statin use and graft
survival. The components of our fully adjusted models
varied by outcome but included statin use and those
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survival: age, sex, race, and if appropriate, body mass
index (BMI), BMI
2, donor type, diabetes, history of pre-
vious transplant, CMV IgG seropositivity, tolerance pro-
tocol, creatinine at 12 months, history of myocardial
infarction (MI), severe liver disease (SLD), and presence
of delayed graft function (DGF). Propensity scores were
generated via logistic regression modeling. All variables
that were assumed to be associated with statins (treat-
ment) were included. The hazard ratios for statin use
v e r s u sn os t a t i nu s ew e r ee x p l o r e dv i at h ef o l l o w i n g
methods and compared. (1) The inverse of the propen-
sity scores were used as weights in a Cox proportional
hazard model. (2) The propensity scores were included
in a Cox proportional hazards model as a continuous
covariate. (3) The propensity scores were ranked into
quintiles and used as a covariate in a Cox proportional
hazards model. The survivorship curves were then com-
pared using log rank tests.
We performed a power calculation using our event
rates for patient deaths and graft failures. Our study
had eighty percent power to detect a 35% difference in
patient survival between the statin and non-statin
g r o u p s .T h es t u d ya l s oh a da tl e a s t8 0 %p o w e rt o
detect a 35% difference in graft failure rate between
the two groups. All analyses were conducted using
SAS software version 8.2 (SAS Institute Inc, Cary, NC).
Data are presented as means ± SD and reported as sig-
nificant if p < 0.05.
Results
Demographics
Baseline patient and donor characteristics are detailed in
Table 1. Two hundred and twenty one (36%) of the 615
kidney transplant recipients met our definition of statin
treatment. Mean ages in the statin-treated and non-sta-
tin-treated groups were 51 (+/- 12) and 48 (+/- 15)
years, respectively (p = 0.002), and the majority of
patients were male (62.4% and 63.3%, p = 0.82) and
white (86.9% and 81.5%, p = 0.08; Table 1). Patients
with older age, higher BMI, hypertriglyceridemia,
hypercholesterolemia, diabetes complicated by end
organ damage and history of myocardial infarction had
higher rates of statin use. Patients who were CMV IGG
positive and those who had higher alkaline phosphatase
levels had lower rates of statin use. Among those with a
complete lipid panel at 12 months (n = 72), there was
no significant difference in LDL (statin and non-statin
groups; 112(46) vs.97(34); p = 0.12) or HDL (statin and
non-statin groups; 45.1(13.9) vs.45.4(16.3); p = 0.93).
There was a trend towards greater statin use over the
course of the study period. The use of statins was asso-
ciated with year of kidney transplant, 22.9% (1998),
27.9% (1999), 47.1% (2000), 45.0% (2001), and 37.7%
(2002), respectively (p < 0.001).
Predictors of statin use
In the multiple logistic regression, older age (OR 1.02;
95% CI, 1.00-1.04), elevated BMI (OR 1.08; 95% CI,
1.03-1.13) and higher cholesterol levels (per 10 mg/dL)
(OR 1.08; 95% CI, 1.03-1.13) were associated with a
higher likelihood of statin use, while higher alkaline
phosphatase levels (OR = 0.995; 95% CI, 0.0.991-0.999)
and CMV IgG positivity (OR 0.64; 95% CI, 0.39 - 1.05)
associated with a lower likelihood of statin use. Statin
use increased over the study period; in order to adjust
for this, we included both the year of transplant and the
sequential transplant identification key into the regres-
sion model, and the predictors for statin use did not
change (Table 2). In our analysis of predictors of statin
use, a number of patients lacked data for one or more
variables. No substantial change in parameter estimates
was seen when substituting average values for missing
data. Steroid use was not associated with increased sta-
tin use. Sixty-three percent of the patients in this study
were received maintenance steroids. The use of statins
increased over time despite the decreasing use of
steroids.
Association of statin use with patient and graft survival
In order to avoid an immortality time bias, we restricted
patient and graft survival analyses to the 615 grafts that
survived at least one year from transplantation. During
an average follow up of 2392 days beyond the first year
after KTX, 152 of 615 kidney transplant patients died.
During an average follow up of 1963 days, 253 of 615
kidney grafts failed (including failure because of death).
As shown in Table 3, there was no significant associa-
tion of statin use with patient survival in unadjusted
analyses (HR 0.99; 95% CI: 0.72-1.37). The association
remained non-significant after adjustment for age, race,
BMI, BMI
2, CMV IgG seropositivity, induction protocol,
creatinine at twelve months, history of myocardial
infarction, and severe liver disease (HR 0.86; 95% CI:
0.60-1.22). We also examined the association between
statin use and graft survival after adjusting for serum
creatinine at 12 months. Similarly, statin use was not
associated with significant improvement in graft survival
(HR 0.97; 95% CI 0.76-1.24). Even after adjustment for
potential confounders such as baseline renal function as
determined by creatinine at 12 months, history of myo-
cardial infarction, severe liver disease, BMI and BMI
2,
statins failed to be associated with improved graft survi-
val (HR 0.93; 95% CI 0.71-1.22). The propensity score
analyses demonstrated slightly lower hazards associated
with the use of statins and slightly narrower confidence
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ciated with statin use in the full models was very similar
to that demonstrated by the use of the propensity
scores. Time to first acute cellular rejection (HR = 1.16;
p = 0.21), after adjustment for recipient age, race, sex,
BMI, PRA, donor type, donor age, antigen matching,
and transplant procedure characteristics, was not asso-
ciated significantly with the use of statins.
Discussion
Data on early statin use in kidney transplant patients
receiving tacrolimus are lacking, and this observational
Table 1 Baseline patient, donor, and transplant procedure characteristics
Characteristics Statin (N = 221) Non-statin (N = 394) All (N = 615) p-value
Baseline patient characteristics
Age at transplant (y; N = 615)* 51 ± 12 48 ± 15 50 0.002
Male (%; N = 614) 62.4 63.3 63.0 0.82
Race (N = 615)
White (%) 86.9 81.5 83.4 0.08
Other (%) 13.1 18.5 16.6
Body Mass Index (kg/m
2; N = 599)* 26 ± 5 25 + 5 26 0.002
Etiology of ESRD (%, N = 615)
DM 18.6 13.4 15.3 0.12
HTN 21.7 17.3 18.9
Other 50.7 59.1 56.1
Unknown 9.0 10.1 9.8
Charlson Co-morbidity Index
Total score (N = 611) 2.13 ± 1.81 2.04 ± 1.90 2.08 0.60
Myocardial Infarction (%, N = 611) 9.9 5.6 7.2 0.05
Severe liver disease (%, N = 611)* 1.8 3.3 2.8 0.27
Previous Transplant (%, N = 615) 17.2 23.3 21.1 0.07
PRA (%; N = 590) 8.1 ± 18.8 9.0 ± 20.0 8.7 0.62
Liver function
AST (U/L; N = 541) 22 ± 11 22 ± 13 22 ± 12 0.95
ALT (U/L; N = 542) 28 ± 19 28 ± 19 28 ± 19 0.95
Alkaline phosphatase (U/L; N = 540)* 97 ± 50 118 ± 113 110 ± 94 0.02
Tbili (mg/dL; N = 539) 0.5 ± 0.2 0.6 ± 0.4 0.6 ± 0.4 0.61
HbsAg positive (%; N = 615) 2.3 0.5 1.1 0.05
Anti-HCV positive (%; N = 615) 6.3 8.4 7.6 0.59
CMV IgG positive (%; N = 612)* 73.3 81.3 78.4 0.02
Total cholesterol (3 m) (mg/dL; N = 467)
Triglycerides (mg/dL; N = 456)
200 ± 47
220 ± 124
181 ± 42
181 ± 118
188
197
< 0.001
< 0.001
Creatinine at 3 mos (mg/dL; N = 590)* 1.8 ± 0.7 1.8 ± 1.1 1.8 0.28
Diabetes with complications (N = 611) 21.3 14.4 16.9 0.03
Donor characteristics Statin (N = 163) Non-statin (N = 552) All (N = 715) p-value
Deceased donor (%; N = 615)* 73.3 75.9 75.0 0.47
Age (y; N = 594) 37 ± 17 37 ± 17 37 ± 17 0.88
A Antigen Mismatch
(%0 Antigen Mismatch, N = 597)
35.6 39.9 38.4 0.75
B Antigen Mismatch
(%0 Antigen Mismatch, N = 601)
29.5 36.5 33.9 0.12
DR Antigen Mismatch
(%0 Antigen Mismatch, N = 597)
25.3 27.6 26.8 0.56
Transplant procedure characteristics
Cold Ischemia Time (min; N = 551)* 1186 ± 745 1327 ± 746 1275 0.03
Delayed graft function (%; N = 615) 19.9 22.3 21.5 0.48
Induction protocol (%, N = 615)* 26.2 25.1 25.5 0.76
*p < 0.05 To convert Total bilirubin from mg/dL to μmol/L, multiply by 17.1; cholesterol from mg/dL to mmol/L, multiply by 0.02586; triglycerides from mg/dL to
mmol/L, multiply by 0.01129; creatinine from mg/dL to μmol/L, multiply by 88.4.
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In our large single-center cohort of kidney transplant
recipients, 36% of patients used statins within the first
year after transplantation, although statins were increas-
ingly used over the course of our study period. The goal
LDL target has also evolved over time. The mean LDL
at 12 months among statin users in our study was
greater than 2.59 mmol/L. We observed greater use of
statins with older age, history of myocardial infarction,
diabetes, higher BMI, and higher serum triglyceride and
cholesterol concentrations. However, older age, elevated
BMI and higher cholesterol levels remained independent
predictors of increased statin use while CMV IgG posi-
tivity and higher alkaline phosphatase levels were pre-
dictors of lower statin use in the multivariate analysis.
While the exposure to statins following kidney trans-
plantation seemed appropriate, statin use within the first
year following kidney transplant was not associated with
better patient or graft survival. Even after adjustment for
multiple variables including age, history of myocardial
infarction, diabetes, sex, baseline creatinine and use of
an induction protocol, statin use, as prescribed to our
patients in this study, was not associated with improved
patient or graft survival. In spite of the potential immu-
nologic benefits of statin therapy on T-cell function, we
did not find a difference in time to first rejection in
patients receiving statins.
These findings expand existing knowledge by examin-
ing the effect of statins in a recent population of new
kidney transplant patients largely managed with a tacro-
limus-based immunosuppressive regimen. The broad
inclusion of all kidney transplantation events at our
institution, and the use of any statin within one year of
transplant lend generalizability to our results. We were
also able to evaluate the effect of baseline patient
comorbidity on patient and graft outcomes in the setting
o fs t a t i nu s eb ye x a m i n i n gt h eC h a r l s o nc o m o r b i d i t y
index, an instrument which has been previously vali-
dated in the kidney transplant population [29].
While only 36% of patients were using statins within
the first 12 months after transplantation, it is also
important to note that the majority of patients included
in our study were treated prior to the published AST/
ASTS clinical practice guidelines regarding the manage-
ment of dyslipidemias in transplant patients [31]. In
addition, underuse of statins has been reported in the
general population [32,33]. The predominant use of
tacrolimus at our institution may also partially explain
the relatively low incidence of statin use in our patient
population, as tacrolimus is known to be less likely to
cause dyslipidemia compared to cyclosporine [26]. The
relatively low prevalence of statin use is similar to that
observed in a recently published observational study [6].
In addition, transplant patients are often on multiple
medications, and because of concerns of drug-drug
interactions and side effects, physicians may be less
likely to prescribe statins for these patients.
In our study, statin use was not associated with
improved graft survival, decreased incidence of acute
rejection, or time to first rejection. These findings are
consistent with results of the only randomized con-
trolled trial examining statin use in kidney transplanta-
tion, the ALERT trial, as well as an observational study
Table 2 Predictors of statin use among kidney transplant recipients
Variable Crude Odds Ratio
(95% CI)*
p-value Adjusted Odds Ratio
(95% CI)
p-value
Age at transplant (per year) 1.02 (1.007 - 1.032) 0.002 1.02 (1.00 - 1.04) 0.005
Body Mass Index 1.05 (1.02 - 1.09) 0.002 1.08 (1.03-1.13) 0.001
Sex 0.96 (0.68 - 1.35) 0.82 1.12 (0.71-1.76) 0.63
Race 1.51 (0.95-2.40) 0.09 1.23 (0.67-2.24) 0.50
MI 1.85 (1.00-3.42) 0.05 N/A
Diabetes with complications 1.61 (1.05-2.47) < 0.0001 N/A
Alkaline phosphatase (per U/L) 0.99 (0.99 - 0.99) 0.02 0.99 (0.99-0.99) 0.017
CMV IgG positive 0.63 (0.43 - 0.93) 0.02 0.64 (0.39 - 1.05) 0.08
Triglycerides (per 10 mg/dL) 1.004 (1.002 - 1.005) < 0.0001 N/A
Cholesterol 1.01 (1.005-1.014) < 0.0001 1.01 (1.005-1.015) < 0.001
Previous Transplant 0.68 (0.45-1.04) 0.07 N/A
Table 3 Association of Statin use with Patient Survival
and Graft Survival
Patient Survival Graft Survival
Crude 0.99 (0.72,1.37) 0.97 (0.76,1.24)
Adjusted
1 0.86 (0.60,1.22) 0.93 (0.71,1.22)
Weighted propensity
1 0.86 (0.68,1.09) 0.98 (0.82,1.18)
Continuous propensity score
2 0.82 (0.58,1.25) 0.90 (0.70,1.17)
Quintiles of Propensity score
2 0.81 (0.57,1.15) 0.89 (0.68,1.16)
1age, sex, race BMI, BMI2, donor type, previous transplant, CMV IgG positivity,
tolerance protocol, creatinine at twelve months, myocardial infarction, severe
liver disease
2Previous transplant, creatinine at twelve months, myocardial infarction,
severe liver disease
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ings in patients receiving primarily tacrolimus based
immunosuppression. In addition, our study shows that
early use of statins within one year after transplantation
does not improve graft survival. Our findings differ from
previous findings in non-transplant kidneys which have
suggested that statins stabilize glomerular filtration rate
(GFR) in patients with advanced kidney dysfunction
[34]. We hypothesize that a potential small immunologic
or non-immunologic benefit of statins on transplanted
kidneys may be overwhelmed by other factors associated
with poor renal function in those patients with subopti-
mal baseline graft function, and that the mechanisms
underlying progression of kidney disease in this setting
may differ in both cause and character from the course
of kidney disease in native kidneys.
The number of studies examining the role of statins in
kidney transplant patients as well as patients with
advanced kidney disease is limited. The ALERT trial is
the only randomized controlled trial of statin use in kid-
ney transplant patients, and it failed to show an
improvement in the primary outcome of major adverse
cardiac event with the use of statins. This may have
been due to inadequate study power as an open-label 2
year extension of the ALERT trial showed that patients
randomized to the fluvastatin group had a reduced risk
of major adverse cardiac events. Another possibility is
that the pathophysiology of cardiovascular disease may
be different in patients with advanced kidney disease
compared to the general population. A randomized con-
trolled trial of atorvastatin in patients with end stage
renal disease on hemodialysis did not show improved
survival in patients receiving atorvastatin(2). On the
other hand, some observational studies have shown
improved patient survival with the use of statins(5). Our
study did not demonstrate improved patient survival
with the use of statins. The reasons underlying the dis-
crepant findings regarding the usefulness of statins in
the transplant population remain poorly defined.
Because of the limited number of available kidney trans-
plant study subjects, studies examining the effect of sta-
tins in this population are often underpowered. Another
possible reason for the lack of strong evidence favoring
statin use in patients with advanced kidney disease is
that cardiovascular disease may already be advanced,
and the cardiovascular mortality risk effectively irreversi-
ble at the time of initiation of statin therapy. In addition,
the pathophysiology of cardiovascular disease may be
unique in the kidney transplant population, and non-tra-
ditional risk factors, which are not targets for statins,
may play a larger role.
Our results must be interpreted in light of several lim-
i t a t i o n s .W ew e r eu n a b l et oe x a m i n ef a c t o r ss u c ha s
pre-transplant treatment with statins, reasons for
initiating and discontinuing statin therapy. The full lipid
profiles are not available for many of our patients. The
potential for relatively short statin use is an additional
limitation of our study; however, 89.9% of patients in
the statin group exceeded the minimum criteria we
defined for statin use. In addition, the indication for sta-
tin use was not uniform across all patients. Statins were
not only prescribed by the transplant team but also by
patients’ personal physicians, including primary care
physicians and specialists. While reflective of real-world
practice, differing prescribing patterns may have affected
the results of the study. Finally, the untreated group,
who despite receiving no therapy, showed a trend
toward lower lipid levels than the treated group. While
the indications and goals of cholesterol management
have evolved over the course of our study period, and
the use of statins in our study may have been less
aggressive than current practice, this finding raises the
possibility that the two groups are systematically differ-
ent and that our results are subject to confounding by
indication.
Since these findings are from a single-center where
patients are followed closely by the transplant group for
the first six months and then at least yearly (but often
much more frequently), thereafter, in conjunction with
the referring nephrologists and primary care physicians,
our findings may have limited application to other mod-
els of post-transplant care. The intensity of follow-up by
the kidney transplant team is also impacted by graft
function, and any complications related to transplanta-
tion. The outcomes of non-fatal MI, stroke, or cardio-
vascular hospitalization were not assessed. Finally, like
other statin studies on kidney transplant patients, this
study may also be underpowered to detect a small effect
size of statins on patient and graft survival. However,
our sample size calculations indicate that a sample size
of 615 patients and a follow up period of 6.6 years pro-
vides relatively sufficient power to detect a major differ-
ence in patient or graft survival between the groups.
It is clear that there are differences among the various
statins in terms of structure, derivatives, metabolism,
potency, and influence on T cell function [10,11]. We
were not able to draw any meaningful conclusions
regarding differences between various statins from our
patient sample. However, we did not find a decrease in
the incidence or time to first rejection among patients
receiving statins.
Conclusion
While studies examining the effect of statins on the out-
comes following renal transplantation vary in their con-
clusions regarding the presence and size of a putative
beneficial effect, all studies to date support the position
that this class of drugs can be used safely in the
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similar to those observed in other patient populations
[35-39]. Of patients who die with a functioning graft,
cardiovascular disease remains a major cause of death;
the potential cardiovascular benefits derived from the
use of statins, by themselves, prompt consideration of
their use. The current AST-ASTS practice guidelines
recommend lipid-lowering therapy for all kidney trans-
plant recipients with fasting triglyceride levels ≥ 5.65
mmol/L, LDL cholesterol ≥ 2.59 mmol/L, or non-HDL-
cholesterol ≥ 3.36 mmol/L, regardless of cardiovascular
status, and notes that statins are the most effective class
of antilipemic drugs for lowering LDL. However, we did
not find a significant influence of statin use on patient
survival; our findings suggest that the pathophysiology
of cardiovascular disease in kidney transplant patients
may differ from that of the general population and that
these patients may have unique risk factors which are
not targeted by statins. Therefore, there is still a need
for large, well designed randomized trials in kidney
transplant patients to establish a positive role of statins
in this particular population.
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